A rational design, synthesis, characterization, and antihypertensive activities of some new substituted benzimidazoles

Medicinal Chemistry Research

Volumn 22, Issue 10, 2013, Pages 4622-4632

  Jain, Anurekha ^a   Sharma, Rajesh ^b   Chaturvedi, S C ^c  

^a B R NAHATA COLLEGE OF PHARMACY   (India)

^b DEVI AHILYA UNIVERSITY   (India)

^c Aurbindo Institute of Pharmacy   (India)

Author keywords

Acute renal hypertension; Angiotensin II antagonist; Benzimidazole; Hypertension

Indexed keywords

2 BUTYL 1 [(2' CYANOBIPHENYL 4 YL)METHYL] 1H BENZIMIDAZOLE 5 DIETHYL AMINE; 2 BUTYL 1 [(2' CYANOBIPHENYL 4 YL)METHYL] 1H BENZIMIDAZOLE 5 ETHYL AMINE; 2 BUTYL 1 [(2' CYANOBIPHENYL 4 YL)METHYL] 1H BENZIMIDAZOLE 5 METHYL AMINE; 2 BUTYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 1H BENZIMIDAZOL 5 YL ACETAMIDE; 2 BUTYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 1H BENZIMIDAZOL 5 YL AMIDE; 2 BUTYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 1H BENZIMIDAZOLE 5 AMINO; 2 BUTYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 1H BENZIMIDAZOLE 5 NITRO; 2 BUTYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] N (1H BENZIMIDAZOL 5 YL)BENZAMIDE; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; GUINEA PIG; RENOVASCULAR HYPERTENSION; SUBSTITUTION REACTION;

EID: 84883456450     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0462-7     Document Type: Article

References (33)

1. Balasubramanian N, Dhake A, Mourya VK (2007) QSAR studies of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines as potent angiotensin II receptor antagonists by MLR and NLR analysis. Arkivoc 1:189-204
2. Bali A, Bansal Y, Sugumaran M, Saggu JS, Balakumar P, Kaur G, Bansal G, Sharma A, Singh M (2005) Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists. Bioorg Med Chem Lett 15:3962-3965
3. Belvisi L, Bravi G, Catalano G, Mabiliab M, Salimbeni A, Scolastico C (1996) A 3D QSAR CoMFA study of nonpeptide angiotensin II receptor antagonists. J Comput Aided Mol Des 10:567-582. doi: 10.1007/BF00134180
4. Carini DJ, Dunica JV, Aldrich PE, Chiu AT, Johnson AL, Pieerce ME, Price WA, Santella JB, Wells GJ, Wexler RR, Wong PC, Yoo S, Timmermans PBMWM (1991) Nonpeptide angiotensin II receptor antagonist: the discovery of series of n-(biphenylmethyl) imidazoles as potent, orally-active antihypertensive. J Med Chem 34:2525-2527
5. Cherinet A, Tesfaye T, Abebe A, Hassen TS, Dawit A, Kelbessa U (2002) Antihypertensive activity of residue from "gebo arekei" locally distilled medicinal spirit from a brew containing lupines albus seeds in renovascular hypertensive guinea pig. Ethio J Health Sci 12:25-31
6. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter MJ (1993) Comparision of angiotensin converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharm 22:579-584
7. Datar PA, Coutinho EC, Srivastava S (2004a) Comparative study of 3D-QSAR techniques on angiotensin II receptor (AT1) antagonists. Lett Drug Design Disc 1(6):115-120
8. Datar PA, Desai PV, Coutinho EC (2004b) A 3D-QSAR of angiotensin II (AT1) receptor antagonistsbased on receptor surface analysis. J Chem Inf Model 44:210-220. doi: 10.1021/ci0341520
9. Ellingboe JW, Antane M, Nguyen TT, Collini MD, Antane S, Bender R, Hartupee D, White V, McCallum J, Park CH (1994) Pyrido[2,3-d]pyrimidine angiotensin II antagonists. J Med Chem 37:542-550. doi: 10.1021/jm00030a013
10. Ferrario CM (1990) The renin-angiotensin system: importance in physiology. J Cardiovasc Pharm 15:S1-S5
11. Gilani AH, Jabeen Q, Ghayur MN, Janbaz KH, Akhtar MS (2005) Studies on the antihypertensive, antispasmodic, bronchodilator and hepatoprotective activities of the Carum copticum seed extract. J Ethnopharmacol 98:127-135
12. Hauser SD, Stade M, Schmidt S, Hanauer G (2005) Cardiovascular parameters in anaesthetized guinea pigs: A safety pharmacology screening model. J Pharmacol Toxicol Methods 52:106-114
13. Jain A, Chaturvedi SC (2008) Rationalization of physicochemical property of some substituted benzimidazole bearing acidic heterocyclic towards angiotensin II antagonist: a QSAR approach. Asian J Biochem 5:330-336
14. 1 receptor antagonist. Sci Pharm 77:555-565
15. 1 receptor antagonist. Med Chem Res doi: 10.1007/s00044-009-9182-z
16. Jason LM, Stephen MT, Vadim AS (2005) An efficient and operationally convenient general synthesis of tertiary amines by direct alkylation of secondary amines with alkyl halides in the presence of Huenig's base. ARKIVOC 287-292
17. Jat RK, Jat JL, Pathak DP (2006) Synthesis of benzimidazole derivatives: as anti-hypertensive agents. Eur J Chem 13:278-285
18. Kaur N, Kaur A, Bansal Y, Shah DI, Bansal G, Singh M (2008) Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin ii receptor antagonists. Bioorg Med Chem 16:10210-10215
19. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T (1996) Synthesis and angiotensin ii receptor antagonist activities of benzimidazole derivatives bearing acidic heterocycle as novel tetrazole bioisosteres. J Med Chem 39:5228-5235
20. Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T (1993a) Nonpeptide angiotensin ii receptor antagonist. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 36:2182-2195
21. Kubo K, Kohara Y, Yoshimura Y, InadaY Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T (1993b) Nonpeptide angiotensin ii receptor antagonist. Synthesis and biological activity of benzimidazoles. J Med Chem 36:1172-1784
22. Kurup A, Garg R, Carini DJ, Hansch C (2001) Comparative QSAR: angiotensin II antagonists. Chem Rev 101:2727. doi: 10.1021/cr000025g
23. Hardman JG, Limbird, LE (2001) Goodman and Gilman's: the pharmacological basis of therapeutics. McGraw-Hill, New York
24. Mostafa MR, Mohamed AO, Tokuda H, Hoda IE (2007) Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt'lymphoma promotion. Bio Med Chem 6489-6496
25. Naka T, Kubo K (1999) a new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Curr Pharm Des 6:453-472
26. Pandya T, Chaturvedi SC (2004) QSAR study of a series of 2-, 3-, 6-substituted quinazolinones as AT1 selective angiotensin II receptor antagonists. Ind J Chem 4300300:2440-2445
27. Pandya T, Chaturvedi SC (2005) Structure-activity relationship study of some triazolinone-based compounds with antagonistic balanced activity on angiotensin II receptor subtypes AT1 and AT2:a three-dimensional quantitative structure-activity relationship investigation. Arzneimittelforschung 55:265-270
28. Pandya T, Pandey SK, Tiwari M, Chaturvedi SC, Saxena AK (2001) 3-D QSAR studies of triazolinone based balanced AT1/AT2 receptor antagonists. Bioorg Med Chem 9:291-300
29. Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M, Van Meel JC, Wienen W, Hauel NH (1993) 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 25:4040-4051
30. 1 receptor antagonist: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. Euro J Med Chem 43:1808-1812
31. 1 receptor antagonists. Bioorg Med Chem Lett 17:2921-2926
32. Yan PZ, Chen BC, Shi H, Jian HJ, Hai LW, Guo LS, Ru QY (2007) QSAR study of angiotensin II antagonists using robust boosting partial least squares regression. Anal Chim Acta 593:68-74. doi: 10.1016/j.aca.2007.04.031
33. Yoo SE, Kim SK, Lee SH, Yi KY, Lee DW (1999) A comparative molecular field analysis and molecular modeling studies on pyridylimidazole type of angiotensin II antagonists. Bioorg Med Chem 7:2971-2976. doi: 10.1016/S0968-0896(99)00245-X